These findings suggest that the decline in levels of GANAB seen during successful treatment-responsive courses in MS patients are directly linked to the rise in GANAB that occurs in conjunction with elevated histological inflammation, as seen in synovial tissue [95]. Here, GANAB is linked to myeloid sarcoma.